Evidence map›Paper›PMID 30514791›Full record

ArticleCancer immunology research2019

Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.

Paul E Clavijo, Jay Friedman, Yvette Robbins, Ellen C Moore, Ernest Smith, Maurice Zauderer, Elizabeth E Evans, Clint T Allen

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04815720 (A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck), which is not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04815720 phase1 / phase2completednot on this mapstarted 2021, after this paper: background citation

A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

TypeinterventionalSponsorVaccinex Inc.Ran2021 to 2024Enrolled49ConditionsRecurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)Armspepinemab + pembrolizumab
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 60 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Paul E ClavijoTranslational Tumor Immunology Program, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland.
Jay FriedmanTranslational Tumor Immunology Program, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland.
Yvette RobbinsTranslational Tumor Immunology Program, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland.
Ellen C MooreTranslational Tumor Immunology Program, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland.
Ernest SmithVaccinex, Inc., Rochester, New York.
Maurice ZaudererVaccinex, Inc., Rochester, New York.
Elizabeth E EvansVaccinex, Inc., Rochester, New York.
Clint T AllenTranslational Tumor Immunology Program, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland. clint.allen@nih.gov.
National Institute on Deafness and Other Communication Disorders · USVaccinex (United States) · USJohns Hopkins University · US

Funding

Characterization and Enhancement of Anti-Tumor Immune Responses in Head and Neck CancerZIADC000087 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI ALLEN, CLINT · 2015 to 2022
$13.5M
Genomics and Proteomics of Head and Neck CancerZIADC000074 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI VAN WAES, CARTER · 2009 to 2022
$11.1M
Genomics and Proteomics of Head and Neck CancerZ01DC000074 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI VAN WAES, CARTER · 2008 to 2008
$607k
Intramural NIH HHS Z01 DC000074Intramural NIH HHS ZIA DC000087NIDCD NIH HHS ZIA DC000074NIDCD NIH HHS ZIA DC000087
6 · The paper itself

Abstract

Tumor infiltration by immunosuppressive myeloid cells, such as myeloid-derived suppressor cells (MDSCs), causes resistance to immunotherapy. Semaphorin4D, originally characterized for its axonal guidance properties, also contributes to endothelial cell migration and survival and modulates global immune cytokine profiles and myeloid cell polarization within the tumor microenvironment. Here, we show how a therapeutic murine Sema4D mAb improves responses to immune-checkpoint blockade (ICB) in two murine carcinoma models. Treatment of tumor-bearing mice with Sema4D mAb abrogated Ly6G

Indexed as

AnimalsAntigens, CDAntineoplastic Agents, ImmunologicalArginaseCell Line, TumorChemokinesCTLA-4 AntigenHumansMiceMyeloid-Derived Suppressor CellsNeoplasmsNeovascularization, PathologicProgrammed Cell Death 1 ReceptorSemaphorinsT-Cell Antigen Receptor SpecificityT-Lymphocyte SubsetsAntigens, CDAntineoplastic Agents, ImmunologicalArginaseCD100 antigenChemokinesCTLA-4 AntigenCTLA4 protein, humanProgrammed Cell Death 1 ReceptorSemaphorins

Identifiers

PMID30514791
PMCPMC8326929
OpenAlexW2902689957

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.